Lung Cancer

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

U.S. veterans face exposures during military service and disparities at home.

Friendship means the world throughout a cancer experience.

Managing side effects from lung cancer treatment with dose reductions is an approach experts have been using more, even though some patients voice concerns about lowering a drug’s impact on the disease.

Patients with extensive-stage small cell lung cancer responded well to the treatment of Trodelvy, according to preliminary results from a phase 2 trial.

Two phase 3 randomized trials focused on evaluating the safety and efficiency of anamorelin to treat adult patients with advanced non-small cell lung cancer linked with weight loss and cachexia.

Dear every oncology team...

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, explains why the approval of Braftovi and Mektovi “It's an important improvement in our armamentarium.”

I had to redefine the relationship with my mother during the most challenging of times.

Patients with advanced non-small cell lung cancer with an EGFR mutation had a greater risk reduction for disease progression with frontline Rybrevant plus Leclaza compared with Tagrisso alone.

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.

Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.

Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Patients with previously treated small cell lung cancer who received a 10-mg dose of tarlatamab had improved responses with no new safety signals.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.

An expert explains the recent movement towards the use of immunotherapy for patients with resectable NSCLC.

The Food and Drug Administration approved a Keytruda regimen to be administered before and after surgery for patients with stage 2, 3A or 3B non-small cell lung cancer.

The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 trial.

People-watching is one of my favorite activities.

Braftovi (encorafenib) with Mektovi (binimetinib) has been approved for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, the agency announced on Wednesday evening.

Measuring cancer DNA in the blood may give clinicians a better idea of which patients with lung cancer need their immunotherapy treatment altered.

After discussions with the FDA, Takeda plans on voluntarily withdrawing Exkivity as a treatment for adults with EGFR exon 20 insertion mutation-positive, locally advanced or metastatic non-small cell lung cancer.

Onvansertib either alone or with standard of care many benefit patients with metastatic pancreatic ductal adenocarcinoma and those with pretreated SCLC.

Patients with lung cancer undergoing anatomic lung resections often had one day home return after completing the surgery, but those with a lower socioeconomic status were less likely to leave the hospital the day after surgery.

Summer came to an end after my cancer diagnosis.

Tecentriq plus carboplatin and pemetrexed may improve efficacy in patients with NSCLC with untreated brain metastases, according to results of a phase 2 trial.

Benmelstobart plus anlontinib with a chemotherapy combination improved survival outcomes for patients with extensive-stage small cell lung cancer.